Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Sahai V, Rothe M, Mangat PK, Garrett-Mayer E, Suhag V, Dib EG, Mehmi I, Kadakia KC, Pisick E, Duvivier HL, Le P, Li R, Michelin DP, Wilcox RE, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL.
Sahai V, et al. Among authors: kadakia kc.
JCO Precis Oncol. 2024 Apr;8:e2300527. doi: 10.1200/PO.23.00527.
JCO Precis Oncol. 2024.
PMID: 38603652